Daniel Merlo - Concepedia

Author

Daniel Merlo

The University of Melbourne ORCID

Also Known As

D Merlo, Daniel Merlo, MERLO, DANIEL FRANCIS, Merlo, Daniel

Publications

577

Citations

H-Index

Concepts

All Affiliations

The University of Melbourne Florey Institute of Neuroscience and Mental Health Monash University The Royal Melbourne Hospital University of Newcastle Australia

About

Daniel Merlo is an author at The University of Melbourne specializing in medicine, multiple sclerosis, and social sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	293
2	Social Sciences	3	3	130
3	Cell Biology	3	3	210
4	Health Sciences	1	1	90
5	Public Health	1	1	73

Daniel Merlo

Publications

506

Citations

H-Index

Page 1

	Year	Citations
Remyelination Is Altered by Bone Morphogenic Protein Signaling in Demyelinated Lesions Jennifer K. Sabo, Tim D. Aumann, Daniel Merlo, Journal of Neuroscience SclerostinDemyelinated LesionsMature OligodendrocytesOsteoporosisNeuroinflammation	2011	90
Common and Low Frequency Variants in MERTK Are Independently Associated with Multiple Sclerosis Susceptibility with Discordant Association Dependent upon HLA-DRB1*15:01 Status Michele D. Binder, Andrew Fox, Daniel Merlo, PLoS Genetics Low Frequency VariantsNeurological DisorderImmunodeficienciesGeneticsImmunology	2016	73
Modulation of bone morphogenic protein signalling alters numbers of astrocytes and oligodendroglia in the subventricular zone during cuprizone‐induced demyelination Holly S. Cate, Jennifer K. Sabo, Daniel Merlo, Journal of Neurochemistry SclerostinPrecursor CellsSynaptic SignalingCellular PhysiologyAdult Subventricular Zone	2010	71
3D Electrospun scaffolds promote a cytotrophic phenotype of cultured primary astrocytes Chew L. Lau, Michelle Kovacevic, Tine S. Tingleff, Journal of Neurochemistry	2014	54
Transcriptomic profiling of astrocytes treated with the Rho kinase inhibitor Fasudil reveals cytoskeletal and pro‐survival responses Chew L. Lau, Victoria M. Perreau, Minghui J. Chen, Journal of Cellular Physiology Glial BiologyNeurogenomicsTranscriptomic ProfilingCell DeathNeurochemical Biomarkers	2011	49
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation Chao Zhu, Tomáš Kalinčík, Dana Horáková, JAMA Neurology	2023	31
Inhibiting Bone Morphogenetic Protein 4 Type I Receptor Signaling Promotes Remyelination by Potentiating Oligodendrocyte Differentiation A. Cole, Rhiannon J. Wood, Jessica L. Fletcher, eNeuro	2019	24
The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis Daniel Merlo, David Darby, Tomáš Kalinčík, Therapeutic Advances in Neurological Disorders	2019	19
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis Chao Zhu, Zhen Zhou, Izanne Roos, Journal of Neurology Neurosurgery & Psychiatry	2022	19
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60 Yi Chao Foong, Daniel Merlo, Melissa Gresle, Journal of Neurology Neurosurgery & Psychiatry	2024	19

Page 1